Fairness Opinion
Duff & Phelps Provided a Fairness Opinion to the Board of Directors of Chiasma, Inc. on Its Sale to Amryt Pharma plc
has signed a definitive merger agreement to be acquired by
Connect With Us
On May 4, 2021, Chiasma, Inc. (NASDAQ: CHMA), a Newton, Massachusetts-based biopharmaceutical company, signed a definitive merger agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, in an all-stock deal.
Duff & Phelps, A Kroll Business, served as a financial advisor to the board of directors of Chiasma and provided an independent fairness opinion in connection with the transaction.
About Chiasma, Inc. (NASDAQ: CHMA)
Chiasma is a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. Goodwin Procter LLP served as legal counsel to Chiasma.
About Amryt Pharma plc (NASDAQ: AMYT, AIM: AMYT)
Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets. Gibson, Dunn & Crutcher LLP served as legal counsel to Amryt.
Fairness and Solvency Opinions
Duff & Phelps Opinions is a global leader in Fairness Opinions and Special Committee Advisory, ranking #1 for total number of U.S. and global fairness opinions over the past 10 years, according to Refinitiv cumulative data from 2013-2022.
Private Capital Markets – Debt Advisory
Kroll has extensive experience raising capital for middle-market companies to support a wide range of transactions.
Mergers and Acquisitions (M&A) Advisory
Kroll’s investment banking practice has extensive experience in M&A deal strategy and structuring, capital raising, transaction advisory services and financial sponsor coverage.
Transaction Advisory Services
Kroll’s Transaction Advisory Services platform offers corporate and financial investors with deep accounting and technical expertise, commercial knowledge, industry insight and seamless analytical services throughout the deal continuum.
Kroll's Investment Banking Team Advised AQREVA and Doctors' Resource Specialists on Its Sale to UnisLink
Kroll's Transaction Advisory Services Practice Rendered Buy-Side Financial and Tax Due Diligence to Multiplan Corporation on Its Acquisition of Benefit Solutions, LLC
Partner with the #1 Global Fairness Opinions Provider
Apr 11, 2022
Special Purpose Acquisition Companies – Half Year 2023 Highlights
Sep 18, 2023
by Chris Janssen, Jennifer Terrell, Mark Kwilosz
